Literature DB >> 26462100

The Impact of Worsening Heart Failure in the United States.

Lauren B Cooper1, Adam D DeVore2, G Michael Felker2.   

Abstract

In-hospital worsening heart failure represents a clinical scenario wherein a patient hospitalized for acute heart failure experiences a worsening of their condition, requiring escalation of therapy. Worsening heart failure is associated with worse in-hospital and postdischarge outcomes. Worsening heart failure is increasingly being used as an endpoint or combined endpoint in clinical trials, as it is unique to episodes of acute heart failure and captures an important event during the inpatient course. While prediction models have been developed to identify worsening heart failure, there are no known FDA-approved medications associated with decreased worsening heart failure. Continued study is warranted.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical trials; Medications; Outcomes; Worsening heart failure

Mesh:

Year:  2015        PMID: 26462100      PMCID: PMC4607925          DOI: 10.1016/j.hfc.2015.07.004

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  36 in total

1.  Heart disease and stroke statistics--2015 update: a report from the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2014-12-17       Impact factor: 29.690

2.  Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).

Authors:  John R Teerlink; John J V McMurray; Robert C Bourge; John G F Cleland; Gadi Cotter; Guillaume Jondeau; Henry Krum; Marco Metra; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J Van Veldhuisen; Aline Frey; Maurizio Rainisio; Isaac Kobrin
Journal:  Am Heart J       Date:  2005-07       Impact factor: 4.749

Review 3.  Cardiac decompensation.

Authors:  A Ramírez; W H Abelmann
Journal:  N Engl J Med       Date:  1974-02-28       Impact factor: 91.245

4.  Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study.

Authors:  Gad Cotter; Marco Metra; Beth A Davison; Stefanie Senger; Robert C Bourge; John G F Cleland; Guillaume Jondeau; Henry Krum; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J van Veldhuisen; Olga Milo; Isaac Kobrin; Maurizio Rainisio; John J V McMurray; John R Teerlink
Journal:  Eur J Heart Fail       Date:  2014-11-05       Impact factor: 15.534

5.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

Authors:  John J V McMurray; John R Teerlink; Gadi Cotter; Robert C Bourge; John G F Cleland; Guillaume Jondeau; Henry Krum; Marco Metra; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J van Veldhuisen; Jim Lewsey; Aline Frey; Maurizio Rainisio; Isaac Kobrin
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

6.  Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).

Authors:  Adrian F Hernandez; Christopher M O'Connor; Randall C Starling; Craig J Reist; Paul W Armstrong; Kenneth Dickstein; Todd J Lorenz; W Brian Gibler; Vic Hasselblad; Michel Komajda; Barry Massie; John J V McMurray; Markku Nieminen; Jean L Rouleau; Karl Swedberg; Robert M Califf
Journal:  Am Heart J       Date:  2008-12-19       Impact factor: 4.749

7.  The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.

Authors:  Gad Cotter; Howard C Dittrich; Beth Davison Weatherley; Daniel M Bloomfield; Christopher M O'Connor; Marco Metra; Barry M Massie
Journal:  J Card Fail       Date:  2008-09-14       Impact factor: 5.712

8.  Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.

Authors:  Scott D Solomon; Joanna Dobson; Stuart Pocock; Hicham Skali; John J V McMurray; Christopher B Granger; Salim Yusuf; Karl Swedberg; James B Young; Eric L Michelson; Marc A Pfeffer
Journal:  Circulation       Date:  2007-08-27       Impact factor: 29.690

9.  The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.

Authors:  Gad Cotter; Edo Kaluski; Karl Stangl; Richard Pacher; Christoph Richter; Olga Milo-Cotter; Loïc Perchenet; Isaac Kobrin; Shoshana Kaplan; Maurizio Rainisio; Aline Frey; Eric Neuhart; Zvi Vered; Jasper Dingemanse; Guillermo Torre-Amione
Journal:  Eur J Heart Fail       Date:  2004-08       Impact factor: 15.534

10.  Repeated hospitalizations predict mortality in the community population with heart failure.

Authors:  Soko Setoguchi; Lynne Warner Stevenson; Sebastian Schneeweiss
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

View more
  8 in total

Review 1.  Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options.

Authors:  Edoardo Gronda; Emilio Vanoli; Stefania Sacchi; Guido Grassi; Giuseppe Ambrosio; Claudio Napoli
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

2.  The implementation cost of a safety-net hospital program addressing social needs in Atlanta.

Authors:  Kara E MacLeod; John M Chapel; Matthew McCurdy; Jasmin Minaya-Junca; Diane Wirth; Anekwe Onwuanyi; Rashon I Lane
Journal:  Health Serv Res       Date:  2021-02-12       Impact factor: 3.734

3.  Vaccine-preventable disease hospitalized patients with heart failure with reduced ejection fraction.

Authors:  Juan Del Cid Fratti; Miguel Salazar; Erwin E Argueta-Sosa
Journal:  Clin Cardiol       Date:  2022-03-10       Impact factor: 3.287

4.  Hospitalized patients with heart failure: the impact of anxiety, fatigue, and therapy adherence on quality of life.

Authors:  Maria Polikandrioti; Ioannis Koutelekos; George Panoutsopoulos; Georgia Gerogianni; Afroditi Zartaloudi; Evangelos Dousis; Fotoula Babatsikou; Georgia Toulia
Journal:  Arch Med Sci Atheroscler Dis       Date:  2019-12-02

5.  Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States.

Authors:  John Bisognano; John E Schneider; Shawn Davies; Robert L Ohsfeldt; Elizabeth Galle; Ivana Stojanovic; Thomas F Deering; JoAnn Lindenfeld; Michael R Zile
Journal:  BMC Cardiovasc Disord       Date:  2021-03-26       Impact factor: 2.298

6.  Aging impairs human bone marrow function and cardiac repair following myocardial infarction in a humanized chimeric mouse.

Authors:  Tina B Marvasti; Faisal J Alibhai; Lukasz Wlodarek; Anne Fu; Shu-Hong Li; Jun Wu; Richard D Weisel; Robert J Cusimano; Maral Ouzounian; Terrence Yau; Ren-Ke Li
Journal:  Aging Cell       Date:  2021-10-06       Impact factor: 9.304

7.  Clinical evidence of Xinbao Pills efficacy on chronic heart failure patients: A protocol for systematic review and meta-analysis.

Authors:  Manhua Huang; Zunjaing Li; Ye Fan; Dongli Li; Quanle Liu; Baijian Chen; Zhe Peng; Banghan Ding
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

Review 8.  In-hospital worsening heart failure: a clinically relevant endpoint?

Authors:  Andrew L Clark; Myriam Cherif; Theresa A McDonagh; Iain B Squire
Journal:  ESC Heart Fail       Date:  2017-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.